NZ332712A - Polypeptide inhibitors of protein farnesyl transferase - Google Patents

Polypeptide inhibitors of protein farnesyl transferase

Info

Publication number
NZ332712A
NZ332712A NZ332712A NZ33271297A NZ332712A NZ 332712 A NZ332712 A NZ 332712A NZ 332712 A NZ332712 A NZ 332712A NZ 33271297 A NZ33271297 A NZ 33271297A NZ 332712 A NZ332712 A NZ 332712A
Authority
NZ
New Zealand
Prior art keywords
alkyl
optionally substituted
farnesyl transferase
protein farnesyl
heteroarylalkyl
Prior art date
Application number
NZ332712A
Inventor
Ellen Myra Dobrusin
Annette Marian Doherty
James Stanley Kaltenbronn
Daniele Marie Leonard
Dennis Joseph Mcnamara
Judith Sebolt-Leopold
Kevon Ray Shuler
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NZ332712A publication Critical patent/NZ332712A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Inhibitors of protein farnesyl transferase enzymes of formula (I), wherein R1, R2, R4 & R21 are independently selected from hydrogen and alkyl, RQ is a 4-alkyleneimidazole group optionally substituted with an alkyl group on either nitrogen atom, A is -CORa, -CONHRa, -CSRa, -C(O)SRa, -C(S)ORa, -C(S)NHRa, -SO2Ra, -CONRa2 or -C(S)NRa2, wherein each Ra is independently selected from alkyl, cycloalkylalkyl, arylalkyl and heteroarylalkyl, R3 is selected from alkyl and optionally substituted cycloalkylalkyl, arylalkyl and heteroarylalkyl and R5 is an optionally substituted C2-C3 alkylene (optionally containing an oxygen atom) terminated with one or two aryl or heteroaryl groups. The compounds are useful in treating cancer, restenosis, psoriasis, endometriosis, atherosclerosis, or viral infections.
NZ332712A 1996-05-22 1997-04-29 Polypeptide inhibitors of protein farnesyl transferase NZ332712A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1611096P 1996-05-22 1996-05-22
US3366296P 1996-12-17 1996-12-17

Publications (1)

Publication Number Publication Date
NZ332712A true NZ332712A (en) 2000-07-28

Family

ID=26688183

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ332712A NZ332712A (en) 1996-05-22 1997-04-29 Polypeptide inhibitors of protein farnesyl transferase

Country Status (18)

Country Link
EP (1) EP0938494A1 (en)
JP (1) JP2000511527A (en)
CN (1) CN1219174A (en)
AU (1) AU728477B2 (en)
BG (1) BG102936A (en)
BR (1) BR9709354A (en)
CA (1) CA2253934A1 (en)
CO (1) CO4960642A1 (en)
CZ (1) CZ376498A3 (en)
EA (1) EA199801031A1 (en)
EE (1) EE9800408A (en)
GE (1) GEP20012500B (en)
IL (1) IL126833A0 (en)
NO (1) NO985405L (en)
NZ (1) NZ332712A (en)
PL (1) PL330120A1 (en)
SK (1) SK161098A3 (en)
WO (1) WO1997044350A1 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981562A (en) * 1996-01-30 1999-11-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6028201A (en) * 1996-01-30 2000-02-22 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU704087B2 (en) * 1996-01-30 1999-04-15 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000504014A (en) * 1996-01-30 2000-04-04 メルク エンド カンパニー インコーポレーテッド Farnesyl-protein transferase inhibitor
US5968965A (en) * 1996-01-30 1999-10-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6300501B1 (en) 1996-05-22 2001-10-09 Warner-Lambert Company Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
US6737410B1 (en) 1997-04-11 2004-05-18 Warner-Lambert Company Inhibitors of protein farnesyl transferase
WO1998046625A1 (en) * 1997-04-11 1998-10-22 Warner-Lambert Company Dipeptide inhibitors of protein farnesyltransferase
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
JP2002513031A (en) * 1998-04-27 2002-05-08 ワーナー−ランバート・カンパニー Glycinamide derivatives with functionalized alkyl and alkenyl side chains as farnesyltransferase inhibitors
WO2000034239A2 (en) 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2477400A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6632818B2 (en) 2000-01-12 2003-10-14 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JP2002188646A (en) * 2000-12-20 2002-07-05 Nsk Ltd Rolling bearing and bearing device
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
WO2005049589A2 (en) * 2003-10-14 2005-06-02 Cadila Healthcare Limited Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases
DE102004015723A1 (en) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
ES2382814T3 (en) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Cis-4 - [(4-chlorophenyl) sulfonyl] -4- (2,5-difluorophenyl) cyclohexanopropanoic acid for cancer treatment
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
WO2008106692A1 (en) 2007-03-01 2008-09-04 Novartis Vaccines And Diagnostics, Inc. Pim kinase inhibitors and methods of their use
KR20100017866A (en) 2007-05-21 2010-02-16 노파르티스 아게 Csf-1r inhibitors, compositions, and methods of use
JP5501227B2 (en) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション 4-Carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
MY174452A (en) 2009-10-14 2020-04-19 Schering Corp Substituted piperidines that increase p53 activity and the uses thereof
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
KR20130006664A (en) 2010-03-16 2013-01-17 다나-파버 캔서 인스티튜트 인크. Indazole compounds and their uses
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2011292261B2 (en) 2010-08-17 2015-05-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
IN2013MN02170A (en) 2011-04-21 2015-06-12 Piramal Entpr Ltd
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2822935B1 (en) 2011-11-17 2019-05-15 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
AU2013323508B2 (en) 2012-09-28 2017-11-02 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CA2927917C (en) 2013-10-18 2022-08-09 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JO3589B1 (en) 2014-08-06 2020-07-05 Novartis Ag Protein kinase c inhibitors and methods of their use
JP6854762B2 (en) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Inhibitor of cyclin-dependent kinase 7 (CDK7)
CA2978518C (en) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US11142507B2 (en) 2015-09-09 2021-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JOP20190055A1 (en) 2016-09-26 2019-03-24 Merck Sharp & Dohme Anti-cd27 antibodies
EP3525785A4 (en) 2016-10-12 2020-03-25 Merck Sharp & Dohme Corp. KDM5 INHIBITORS
IL315837A (en) 2017-04-13 2024-11-01 Sairopa B V Anti-sirp alpha antibodies
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2024180169A1 (en) 2023-03-02 2024-09-06 Carcimun Biotech Gmbh Means and methods for diagnosing cancer and/or an acute inflammatory disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352705A (en) * 1992-06-26 1994-10-04 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
CA2172125A1 (en) * 1993-09-30 1995-04-06 S. Jane Desolms Inhibitors of farnesyl-protein transferase
KR100362338B1 (en) * 1993-11-05 2003-04-08 워너-램버트 캄파니 Protein: Substituted Di- and Tripeptide Inhibitors of Farnesyl Transferase
US5571792A (en) * 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase

Also Published As

Publication number Publication date
PL330120A1 (en) 1999-04-26
GEP20012500B (en) 2001-07-25
CZ376498A3 (en) 1999-02-17
CA2253934A1 (en) 1997-11-27
AU728477B2 (en) 2001-01-11
NO985405L (en) 1999-01-19
EE9800408A (en) 1999-06-15
EA199801031A1 (en) 1999-06-24
BR9709354A (en) 1999-08-10
BG102936A (en) 1999-09-30
WO1997044350A1 (en) 1997-11-27
JP2000511527A (en) 2000-09-05
IL126833A0 (en) 1999-08-17
CN1219174A (en) 1999-06-09
NO985405D0 (en) 1998-11-20
SK161098A3 (en) 2000-06-12
AU2805897A (en) 1997-12-09
CO4960642A1 (en) 2000-09-25
EP0938494A1 (en) 1999-09-01

Similar Documents

Publication Publication Date Title
NZ332712A (en) Polypeptide inhibitors of protein farnesyl transferase
TW369617B (en) Plastic articles for medical use
EP1068357A4 (en) THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BASED ON THE ROLE OF THE CXCR-4 GENE IN ONCOGENESIS
FI935673A0 (en) Amino-substituted pyrazoler
AP9701007A0 (en) Substituted azetidin-2-ones for treatment of atherosclerosis.
GR3036017T3 (en) Heterocyclic fungicides
ATE184295T1 (en) MODIFIED SILOXANES POLYOLEFIN COPOLYMERS
EP0528858A4 (en) Inhibitors of dipeptidyl-aminopeptidase type iv
MY126779A (en) Benzoylcyclohexanediones, process for their preparation and their use as herbicides and plant growth regulators
MD1861G2 (en) Derivatives of the 6-arylpyrido [2,3-d] pyrimidines and naphthyridines, parmaceutical composition on base thereof, methods of treatment and inhibition of the tyrosine kinaze receptor cell proliferation and migration
ES2184268T3 (en) OLIGOMEROS OF ORGANOSILANOS.
DE69415343D1 (en) 2'-AMIDO AND 2'-PEPTIDO-MODIFIED OLIGONUCLEOTIDES
PL315747A1 (en) Fungicidal cyclic amides
MX9708621A (en) 'beta'-ADRENERGIC AGONISTS.
DK1149092T3 (en) 4- and 5-alkynyloxindoles and 4- and 5-alkenyloxindoles
PT97746A (en) PROCESS OF ENANTIO-SELECTIVE PREPARATION OF PHENYL-ISO-SERIN DERIVATIVES
AU570920B2 (en) 1-aryloxy-2,3,4,5-tetrahydro-3-benzazepines
AU3947785A (en) Organosiloxanes
MX9708452A (en) Inhibitors of bacterial sialidase and methods of making and using the same.
ATE283075T1 (en) SUBSTRATES CONTAINING POLYPHOSPHAZENE AS A MATTRICE FOR CULTURE CELLS
DE69026954D1 (en) CONTINUOUS CELL CULTURE SYSTEM OF HIGH TIGHTNESS
NO983283L (en) Hydrocamic acid-based collagenase inhibitors
ATE232732T1 (en) 2',5'-PHOSPHORTHIOATE/PHOSPHODIESTER OLIGOADENYLATE AND THEIR ANTIVIRAL USES
TR200003877T2 (en) Hiydroxamic acid derivatives, which are inhibitors of human CD23 production and TNF release
NZ334702A (en) Cycloalkyl inhibitors of protein farnesyltransferase